Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course

Delehaye F., Rouger J., Brossier D., Suttorp M., Güneş A. M., Sedlacek P., ...Daha Fazla

Annals of Hematology, cilt.102, sa.3, ss.563-570, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 102 Sayı: 3
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1007/s00277-022-05024-1
  • Dergi Adı: Annals of Hematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.563-570
  • Anahtar Kelimeler: Leukemia, Chronic myeloid leukemia, Children, Pediatric, Anemia, INTERNATIONAL REGISTRY, CHILDREN, SURVIVAL, DISCRIMINATION, MANAGEMENT, FEATURES, EUTOS
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.The clinical presentation of chronic myeloid leukemia (CML) at diagnosis differs in children compared to adults. At younger age, anemia appears to be frequent at diagnosis, but its prevalence and its impact on prognosis are not well known. In the International Registry of Childhood CML, we selected children and adolescents in chronic phase at diagnosis of CML and treated upfront with imatinib. We examined their hemoglobin level at diagnosis according to the WHO grades to assess the prevalence of anemia and its impact on response to tyrosine kinase inhibitors (TKIs). Data on 430 patients were included. Anemia at diagnosis was observed in 350 patients (81%), with a mean hemoglobin level of 96.4 g/l (SD 23.6). Among them, 182 patients (52%) presented with moderate anemia and 110 (31%) with severe anemia while 58 (17%) had mild anemia. Compared with mild and no anemia, moderate and severe forms were significantly associated with younger age at diagnosis, asthenia, splenomegaly, and increased leukocyte and basophil counts. Delays in achieving major and deep molecular responses were significantly increased for patients with moderate and severe anemia, and also failure of imatinib treatment was more frequent in these two sub-cohorts. However, hemoglobin level was not significantly associated with survival. Anemia at diagnosis of pediatric CML was frequent and may be considered as a prognostic factor.